A Ludwig Cancer Research study has deciphered a complex molecular conversation between cancer and immune cells that is key to orchestrating the successful invasion of tumors by T cells that kill cancer cells.
Jun 10, 2019
0
68
A common genetic deficiency empowers glioblastoma to broadcast a molecular message to the wrong type of immune cell, summoning macrophages that protect and nurture the brain tumor instead of attacking it, researchers at The ...
Jun 10, 2019
0
75
Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed, hierarchical order. Accordingly, such cancer stem ...
May 27, 2019
0
95
In a new study, Yale Cancer Center scientists have demonstrated a powerful method to analyze how tumor cells are altered as they metastasize, or spread, to the brain. The research, published in the journal Cell Reports, may ...
Apr 30, 2019
0
114
A research team led by investigators at Massachusetts General Hospital (MGH) and the Massachusetts Institute of Technology (MIT) has found that combining a specialized version of an antihypertension drug with immune checkpoint ...
Apr 29, 2019
0
112
UNC Lineberger Comprehensive Cancer Center researchers presented innovative new strategies for using tiny particles the size of a DNA molecule or the width of a human hair to boost cancer treatment as part of the Carolina ...
Apr 22, 2019
0
0
A new study reveals the mechanisms whereby low dose photodynamic therapy affects the microstructure of vessels. Using co-cultures of pericytes and endothelial cells in vitro, the authors show that low dose photodynamic therapy ...
Apr 5, 2019
0
0
Immunotherapy, using the body's own immune system to target and destroy cancer cells, is one of the most promising frontiers in cancer research, but many patients do not respond to the therapies for reasons not fully understood.
Mar 21, 2019
0
389
Columbia researchers have learned why some glioblastomas—the most common type of brain cancer—respond to immunotherapy. The findings could help identify patients who are most likely to benefit from treatment with immunotherapy ...
Feb 15, 2019
0
7
(HealthDay)—Neoadjuvant administration of programmed cell death protein 1 (PD-1) blockade seems to enhance local and systemic antitumor immune response in glioblastoma, according to a study published online Feb. 11 in Nature ...
Feb 13, 2019
0
2
